


CERTIFICATE OF ELECTRONIC SUBMISSION	
September 21, 2006	
Date	Charles P. Landrum

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
McBride *et al.*

Serial No.: 10/701,038

Filed: November 4, 2003

For: P153 AND P156 ANTIGENS FOR THE
IMMUNODIAGNOSIS OF CANINE AND
HUMAN EHRLICHIOSES AND USES
THEREOF

Group Art Unit: 1645

Examiner: Zeman, R.

Atty. Dkt. No.: CLFR:235US

SUPPLEMENTAL APPEAL BRIEF

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

TABLE OF CONTENTS

I.	REAL PARTY IN INTEREST.....	4
II.	RELATED APPEALS AND INTERFERENCES	4
III.	STATUS OF THE CLAIMS	4
IV.	STATUS OF AMENDMENTS.....	4
V.	SUMMARY OF CLAIMED SUBJECT MATTER.....	5
VI.	GROUND OF REJECTION TO BE REVIEWED ON APPEAL	7
VII.	ARGUMENT.....	7
	A. Rejections under 35 U.S.C. § 112	7
	1. Claims 6, 15, and 27-34 Satisfy the Written Description Requirement of 35 U.S.C. § 112, first paragraph	7
	2. Claims 6, 15, and 27-34 are Definite and Satisfy the Requirements of 35 U.S.C. § 112, second paragraph	11
	B. Objections under 37 C.F.R. § 1.175	12
	1. Claim 30 Further Limits the Subject Matter of Claim 6.....	12
	2. Claims 31, 32, 33, and 34 are Distinct from Claims 15, 27, 28, and 29	13
	C. Grouping of Claims	13
	D. Conclusion.....	13
VIII.	CLAIMS APPENDIX	15
IX.	EVIDENCE APPENDIX	17
X.	RELATED PROCEEDINGS APPENDIX.....	25

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
McBride *et al.*

Serial No.: 10/701,038

Filed: November 4, 2003

For: P153 AND P156 ANTIGENS FOR THE
IMMUNODIAGNOSIS OF CANINE AND
HUMAN EHRLICHIOSES AND USES
THEREOF

Group Art Unit: 1645

Examiner: Zeman, R.

Atty. Dkt. No.: CLFR:235US

SUPPLEMENTAL APPEAL BRIEF

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Appellants hereby submit this Supplement Appeal Brief to the Board of Patent Appeals and Interferences in response to the Notification of Non-Compliant Appeal Brief dated September 1, 2006.

It is believed that no additional fees are due; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski Deposit Account No. 50-1212/CLFR:235US.

I. REAL PARTY IN INTEREST

The real party in interest is the assignee, Research Development Foundation, Carson City, Nevada.

II. RELATED APPEALS AND INTERFERENCES

There are no related appeals or interferences.

III. STATUS OF THE CLAIMS

Appellants originally filed claims 1-26. In the Response filed January 18, 2005 to the Restriction Requirement dated December 15, 2004 Applicants elected Group II, Claims 6 and 15, and elected to pursue SEQ ID NO: 2. Appellants withdrew claims 1-5, 7-14, and 16-26 from consideration. In the Response filed on September 19, 2005 to the Office Action dated April 25, 2005, which was supplemented with the Response of October 17, 2005 to Notice of Non-Compliant Amendment dated September 30, 2005, claim 6 was amended and new claims 27-34 were added. The Office Action dated January 9, 2006 maintained the rejection of claims 6, 15 and 27-34 as lacking written description. Thus, claims 6, 15 and 27-34 are currently pending, stand rejected, and are appealed. (*see* VIII. Claims Appendix).

IV. STATUS OF AMENDMENTS

The final Office Action mailed January 9, 2006 acknowledges the amendments included in the Response to Notice of Non-Compliant Amendment of October 17, 2005 and in the Response to Final Office Action of September 19, 2005. The Response of September 19, 2005 included amendment of claim 6 and the addition of claims 27-34. Applicants' Response on

March 9, 2006 to Final Office Action mailed January 9, 2006 contained claim amendments addressing all issues outstanding in the Final Office Action mailed January 9, 2006. The Advisory Action mailed March 31, 2006, denied entry of the March 9, 2006 amendments filed with the Response to Final Office Action filed March 9, 2006.

V. SUMMARY OF CLAIMED SUBJECT MATTER

The principal claim, claim 6, is directed to an isolated and purified polypeptide of *Ehrlichia canis* immunoreactive surface protein p153 encoded for by DNA selected from the group consisting of (a) isolated DNA which encodes a p153 protein having the amino acid sequence shown in SEQ ID NO: 2; (b) isolated DNA differing from the isolated DNA of (a) in codon sequence due to the degeneracy of the genetic code; (c) isolated DNA sequence comprising nucleotides 1080 to 1990 of *Ehrlichia canis* immunoreactive surface protein p153 gene; (d) isolated DNA sequence comprising nucleotides 1950 to 2950 of *Ehrlichia canis* immunoreactive surface protein p153 gene; and (e) isolated DNA sequence comprising nucleotides 2940 to 4220 of *Ehrlichia canis* immunoreactive surface protein p153 gene. Support for this embodiment of the invention is found, at least on page 10, lines 1-10 and page 15, lines 12-18 of the specification.

Dependent claim 15 is directed to a composition comprising an isolated and purified polypeptide of *Ehrlichia canis* immunoreactive surface protein p153 as defined in claim 6. Support for this embodiment of the invention is found, at least on page 16, lines 5-7 of the specification.

Dependent claim 27 is directed to a polypeptide described in claim 6 that is immobilized on a surface. Support for this embodiment of the invention is found, at least on page 16, line 17 to page 17, line 3 of the specification.

Dependent claim 28 is directed to a polypeptide of claim 27 wherein the surface is a membrane. Support for this embodiment of the invention is found, at least on page 16, line 17 to page 17, line 3 of the specification.

Dependent claim 29 is directed to a polypeptide of claim 27 wherein the surface is a microtiter plate. Support for this embodiment of the invention is found, at least on page 16, line 17 to page 17, line 3 of the specification.

Dependent claim 30 is directed to a polypeptide of claim 6 wherein the polypeptide is an *Ehrlichia canis* immunoreactive surface protein p153 polypeptide. Support for this embodiment of the invention is found, at least on page 12 to page 14 of the specification.

Dependent claim 31 is directed to a composition comprising the peptide of claim 30. Support for this embodiment of the invention is found, at least on page 16, lines 5-7 of the specification.

Dependent claim 32 is directed to the polypeptide of claim 30 immobilized on a surface. Support for this embodiment of the invention is found, at least on page 16, line 17 to page 17, line 3 of the specification.

Dependent claim 33 is directed to the polypeptide of claim 32 wherein the surface is a membrane. Support for this embodiment of the invention is found, at least on page 16, line 17 to page 17, line 3 of the specification.

Dependent claim 34 is directed to the polypeptide of claim 32 wherein the surface is a microtiter plate. Support for this embodiment of the invention is found, at least on page 16, line 17 to page 17, line 3 of the specification.

VI. GROUNDS OF REJECTION TO BE REVIEWED ON APPEAL

The issues addressed in this Appeal Brief include:

(a) Whether the written description for the sequence of an *Ehrlichia canis* immunoreactive surface protein p153 gene is sufficient under 35 U.S.C. § 112, first paragraph;

(b) Whether claims 6, 15, and 27-34 are definite relative to the sequence for an *Ehrlichia canis* p153 gene;

(c) Whether the subject matter of claim 30 directed to a full length p153 polypeptide, further limits claim 6 directed to segments of p153; and

(d) Whether sufficient antecedent basis is present for the term “surface” in claims 33 and 34.

VII. ARGUMENT

A. Rejections under 35 U.S.C. § 112

1. Claims 6, 15, and 27-34 Satisfy the Written Description Requirement of 35 U.S.C. § 112, first paragraph

Claims 6, 15, and 27-34 are rejected as failing to comply with the written description requirement because the claims allegedly contain subject matter not described in the specification in such way as to reasonably convey to one skilled in the relevant art that the inventors, at the time the application was filed, had possession of the claimed invention. The

Action alleges that no baseline sequence is provided for the *E. Canis* immunoreactive surface protein p153 gene and none of the claimed proteins meet the written description requirement. The Action cites *Fiers v. Revel*, 984 F.2d 1164, 25 USPQ2d 1601, and *Amgen, Inc. v Chugai Pharmaceutical*, 927 F.2d 1200, 18 USPQ2d 1016, in support of the rejection. Applicants disagree.

Applicants have addressed the Examiner's concerns in their Response to Final Office Action by submitting amended claims containing a reference to GenBank accession number AF252298. However, the Examiner denied entry of these claims. Nonetheless, the presently pending claims satisfy the written description requirement.

First, it is Applicants' position that the Examiner has failed to make out a prima facie case of lack of written description. As stated in the MPEP § 2163(II)(A):

The examiner has the initial burden, after a thorough reading and evaluation of the content of the application, of presenting evidence or reasons why a person skilled in the art would not recognize that the written description of the invention provides support for the claims. There is a strong presumption that an adequate written description of the claimed invention is present in the specification as filed, *Wertheim*, 541 F.2d at 262, 191 USPQ at 96 [] The inquiry into whether the description requirement is met is a question of fact that must be determined on a case-by-case basis. . .

The MPEP also provides that an Examiner should review the entire application to understand how the applicant provides support for the claimed invention. MPEP § 2163(II)(A)(2) states:

Prior to determining whether the disclosure satisfies the written description requirement for the claimed subject matter, the examiner should review the claims and the entire specification, including the specific embodiments, figures, and sequence listings, to understand how applicant provides support for the various features of the claimed invention. . .

The present specification clearly sets forth the sequences of an *Ehrlichia canis* immunoreactive surface protein p153 polypeptide and gene as provided in GenBank accession number AF252298. The Examiner's statement that "no baseline sequence is provided for [] the *Ehrlichia canis* immunoreactive surface protein p153 gene," does not establish prima facie a lack of written description, particularly in light of GenBank accession number AF252298. None of the reasons set forth in the Final Office Action establish any fact that would shift the burden of establishing adequate written description to the Applicants. The Examiner has failed to provide evidence or reason why the claims read in light of the specification lack written description.

Second, Applicants provide a written description for an *Ehrlichia canis* immunoreactive surface protein p153 polypeptide and gene in the specification as GenBank accession number AF252298. The specification on page 14, line 9 to line 14 discloses the revised sequence for the *Ehrlichia canis* p153 gene and polypeptide as GenBank accession number AY156950. However, the AF252298 record was updated to include the revised sequence instead of establishing the new accession number. The current AF252298 record (Exhibit 1) states that the revised sequence (a) was submitted on September 30, 2002 and (b) replaced the earlier version of accession number AF252298 (gi:12658962; Exhibit 2). Exhibit 1 is a copy of the current GenBank entry for accession number AF252298 and Exhibit 2 is a copy of GenBank entry prior to replacement with the full length p153 sequence, each of which were made of record in Applicants' Response dated September 19, 2005. Thus, GenBank accession number AF252298 provides a baseline sequence for amino acid and nucleic acid sequences of the *E. canis* immunoreactive surface protein p153 protein and gene, respectively. One of skill in the art, based on disclosure of the nucleic acid and amino acid sequence of the *Ehrlichia canis* immunoreactive surface protein p153, *i.e.*, GenBank accession number AF252298, had access to

the sequence of the *Ehrlichia canis* immunoreactive surface protein p153 and would have reasonably concluded that Applicants possessed the subject matter claimed as of the priority date of the present application, November 4, 2002.

In addition, the present invention is distinct from the facts underlying the *Fiers* and *Amgen* cases, which were cited in support of the rejection. In these cases the conception date of a nucleic acid sequence was the date the actual DNA sequence was known. The cases held that the description of methods for isolating a fragment of DNA and methods for isolating a corresponding mRNA is insufficient description of a nucleic acid sequence or an amino acid sequence encoded by the nucleic acid. In contrast, in the present case the DNA sequence was known and submitted to GenBank prior to the priority date of the present application. The present application does not rely on methods of isolation for identifying or describing the nucleic acid or polypeptide sequences, it discloses the sequences in the application by reference to the GenBank accession number. Therefore, the present application provides more than the mere description of the methods for isolating a DNA sequence. Thus, the holdings in *Fiers* and *Amgen* are not relevant to the present application. Because the Applicants were in possession of the invention and the GenBank accession number describes the claimed invention in sufficient detail, one skilled in the art can reasonably conclude that the inventor had possession of the claimed invention.

Applicants note that none of the rejections speak to the insufficiency of GenBank accession number AF252298 and no notification of informalities regarding the sequence listing was conveyed to the Applicants during prosecution.

2. Claims 6, 15, and 27-34 are Definite and Satisfy the Requirements of 35 U.S.C. § 112, second paragraph

Claims 6, 15, and 27-34 are rejected under 35 U.S.C. § 112, second paragraph as being indefinite for failing to particularly point out and distinctly claim the subject matter Applicants regard as their invention. The claims are allegedly vague and indefinite for the following reasons: (a) claim 6 does not a baseline sequence, and (b) claims 33 and 34 lack antecedent basis for “surface.”

a) Claim 6, 15, 27-34 are Definite

The Examiner alleges that no baseline sequence is provided for the claimed gene. This issue was addressed by Applicants in the claim amendments submitted in their Response After Final Office Action by including a reference to GenBank accession number AF252298. The amendment was not entered by the Examiner. Nonetheless, as discussed above and incorporated here by reference, one of skill in the art reading the claims in light of the specification would have readily recognized the baseline sequence of the *E. canis* immunoreactive surface protein p153 as GenBank accession number AF252298. The pending claims satisfy 35 U.S.C. § 112, second paragraph.

b) Claims 33 and 34

The Examiner indicates that claims 33 and 34 lack antecedent basis for the term “surface.” Again, Applicants addressed this rejection in amendments not entered by the Examiner. However, this insufficiency is easily addressed by clarification of claim dependency and Applicants can address upon remand to the Examiner.

B. Objections under 37 C.F.R. § 1.175

1. Claim 30 Further Limits the Subject Matter of Claim 6

Claim 30 is objected to as failing to further limit the subject matter of a previous claim. Applicants respectfully disagree.

Claim 30 does further limit the subject matter of claim 6. Claim 6 is directed to segments of the *E. canis* p153 protein and reads in part "...isolated DNA which encodes a p153 protein having the amino acid sequence shown in SEQ ID NO: 2." SEQ ID NO:2 represents a segment of the P153 protein. Claim 30 is directed to the full length *E. canis* protein and reads "The isolated and purified polypeptide of claim 6, wherein the polypeptide is an *Ehrlichia canis* immunoreactive surface protein p153 polypeptide." The full length *E. canis* p153 protein is described in the specification on page 14 that reads:

Anti-p43 antibody reacted with a native protein of approximately 200 kD in *E. canis* whole cell lysates. Furthermore, this 200 kD protein was also recognized by sera from an *E. canis* infected dog (Figure 5). A partial gene sequence previously identified as p43 (N-terminal portion of the p153) assigned GenBank accession number AF252298. The amended sequencing encoding p153 was assigned the GenBank accession number AY156950.

GenBank accession number AF252298 was amended to encompass the sequence of GenBank accession number AY15690, see above for a more detailed discussion. GenBank accession AF252298 describes the full length *E. canis* p153 polypeptide. The polypeptide segments of claim 6, in particular the segment having the amino acid sequence of SEQ ID NO:2, are not equivalent to the *Ehrlichia canis* immunoreactive surface protein p153 polypeptide of claim 30. Thus, claim 30 is distinct from and further limits the claim 6 to the full length polypeptide sequence.

2. Claims 31, 32, 33, and 34 are Distinct from Claims 15, 27, 28, and 29

Claims 31, 32, 33 and 34 are objected to as being substantial duplicates of claims 15, 27, 28, and 29. This objection is related to the previously argued objection related to the alleged failure to further limit the subject matter of a previous claim. The arguments set forth above relating to the objection of claim 30 are incorporated here by reference. Since claim 30 is distinct from claim 6, claims 31, 32, 33, and 34, which depend from claim 30, are distinct from claims 15, 27, 28, and 29, which depend from claim 6.

C. Grouping of Claims


The evidence of record overwhelmingly indicates that the present invention satisfies the requirements under 35 U.S.C. § 112. In particular, GenBank accession AF252298 describes the amino acid and nucleic acid sequence of the *E. Canis* immunoreactive surface protein p153 and provides a basis for nucleic acid and amino acid sequences presently claimed. The claims stand or fall together.

D. Conclusion

For the above-argued reasons, Appellants respectfully request that the rejection of claims 6, 15, and 27-34 be reversed. Appellants have provided arguments that overcome the pending rejections. Appellants respectfully submit that the Examiner's conclusion that the claims should be rejected is unwarranted.

It is therefore again requested that the Board overturn the Examiner's rejection.

Respectfully submitted,



Charles P. Landrum
Reg. No. 46,855
Agent for Appellants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201
(512) 536-4598 (facsimile)

Date: September 21, 2006

VIII. CLAIMS APPENDIX

6. (Previously presented) An isolated and purified polypeptide of *Ehrlichia canis* immunoreactive surface protein p153 encoded for by DNA selected from the group consisting of:

(a) isolated DNA which encodes a p153 protein having the amino acid sequence shown in SEQ ID NO: 2;

(b) isolated DNA differing from the isolated DNA of (a) in codon sequence due to the degeneracy of the genetic code;

(c) isolated DNA sequence comprising nucleotides 1080 to 1990 of *Ehrlichia canis* immunoreactive surface protein p153 gene;

(d) isolated DNA sequence comprising nucleotides 1950 to 2950 of *Ehrlichia canis* immunoreactive surface protein p153 gene; and

(e) isolated DNA sequence comprising nucleotides 2940 to 4220 of *Ehrlichia canis* immunoreactive surface protein p153 gene.

15. (Previously presented) A composition comprising a p153 polypeptide of claim 6.

27. (Previously Presented) The isolated and purified polypeptide of claim 6, wherein the protein is immobilized on a surface.

28. (Previously Presented) The isolated and purified polypeptide of claim 27, wherein the surface is a membrane.

29. (Previously Presented) The isolated and purified polypeptide of claim 27, wherein the surface is a microtiter plate.

30. (Previously Presented) The isolated and purified polypeptide of claim 6, wherein the polypeptide is an *Ehrlichia canis* immunoreactive surface protein p153 polypeptide.

31. (Previously Presented) A composition comprising a p153 polypeptide of claim 30.

32. (Previously Presented) The isolated and purified polypeptide of claim 30, wherein the protein is immobilized on a surface.

33. (Previously Presented) The isolated and purified polypeptide of claim 30, wherein the surface is a membrane.



34. (Previously Presented) The isolated and purified polypeptide of claim 30, wherein the surface is a microtiter plate.

IX. EVIDENCE APPENDIX

Exhibit 1 – Copy of GenBank accession number AF252298 (gi:37528969), made of record in Applicants Response dated September 19, 2005 to the non-final Office Action mailed April 25, 2005 as Exhibit 2.

Exhibit 2 – Copy of GenBank accession number AF252298 (gi:12658962), made of record in Applicants Response dated September 19, 2005 to the non-final Office Action mailed April 25, 2005 as Exhibit 1.

EXHIBIT 1



[My NCBI](#) [Sign In](#) [Register](#)

[PubMed](#) [Nucleotide](#) [Protein](#) [Genome](#) [Structure](#) [PMC](#) [Taxonomy](#) [OMIM](#) [Books](#)

Search for

[Limits](#) [Preview/Index](#) [History](#) [Clipboard](#) [Details](#)

Display Show [Send to](#)

Range: from to
☐ Reverse complemented strand
 Features: ☐ SNP ☒ CDD ☐

☐ 1: [AF252298](#). Reports *Ehrlichia canis* 2...[gi:37528969]

[Links](#)

[Comment](#) [Features](#) [Sequence](#)

LOCUS AF252298 4266 bp DNA linear BCT 06-OCT-2003
DEFINITION *Ehrlichia canis* 200 kDa immunoreactive glycoprotein gene, complete cds.
ACCESSION AF252298
VERSION AF252298.2 GI:37528969
KEYWORDS .
SOURCE *Ehrlichia canis*
ORGANISM *Ehrlichia canis*
 Bacteria; Proteobacteria; Alphaproteobacteria; Rickettsiales; Anaplasmataceae; Ehrlichia.
REFERENCE 1 (bases 1 to 4266)
AUTHORS McBride, J.W., Corstvet, R.E., Breitschwerdt, E.B. and Walker, D.H.
TITLE Immunodiagnosis of *Ehrlichia canis* infection with recombinant proteins
JOURNAL J. Clin. Microbiol. 39 (1), 315-322 (2001)
PUBMED [11136790](#)
REFERENCE 2 (bases 1 to 4266)
AUTHORS McBride, J.W., Comer, J.E. and Walker, D.H.
TITLE Novel Immunoreactive Glycoprotein Orthologs of *Ehrlichia* spp
JOURNAL Ann. N. Y. Acad. Sci. (2003) In press
REFERENCE 3 (bases 1 to 4266)
AUTHORS McBride, J.W. and Walker, D.H.
TITLE Direct Submission
JOURNAL Submitted (04-APR-2000) Pathology, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555, USA
REFERENCE 4 (bases 1 to 4266)
AUTHORS McBride, J.W. and Walker, D.H.
TITLE Direct Submission
JOURNAL Submitted (30-SEP-2002) Pathology, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555, USA
COMMENT On Oct 6, 2003 this sequence version replaced gi:12658962.
FEATURES Location/Qualifiers
 source 1..4266
 /organism="Ehrlichia canis"
 /mol_type="genomic DNA"
 /db_xref="taxon:944"
 CDS 1..4266
 /note="gp200"
 /codon_start=1
 /transl_table=11
 /product="200 kDa immunoreactive glycoprotein"
 /protein_id="AAK01145.2"
 /db_xref="GI:37528970"

```

/translation=*MSDPKQGSFPRQHQTNPSGGIQDQSQQQQQQBQDQQQGA VGGAVEN
SPIERERVAAPESEDLYTVIIPKCKRTAAPILEKKEFTPEPKVEUDEDLPPTLPPTTY
SGRGYDDWQVSMPTVSRGIYQFPPIVQDSNLYSSIGGVPOEAYQYDAARAGGPRKFLYG
PYTFSNGQEIIMDFEFTDPWEDWRNAVLENGKEIKREMLTSGPVRDIADIVASHQDLS
EDQVEEILDIIIMNESSIABGISNPLIADVDNNPVKGAAXNMTLMHLVYACDVEPRIV
KALGEVENDEGDLQANAYNVLDSEGNLPLHRAAKMCTGDXLKLCKEKTETDTDFICTANF
ANQSPHIIITQKPDOSVLDIEEFTSERNLDFGLVGGGSKNPLHHAVERLPPVILKGVMD
IEVMSSEPODLVNDPDPYFNTLAHYAVKNKNADLTLENHLKASGADIAVRNVVGRAPI
HVASSNGKANAVSGLVSCGIDVNEGQDVKQDTPLHIAVEGGSMETVLAVLNQRGADVSV
QMNDCUTPHLSAAKYGDIGVICALSSAKPNIKGSDTVAKSLIMEDYKGFPTPLHFVAGG
GSRDTFRVVRKQFYKCIDLATIRAAALMQDRSGGELVNLGDFESENILGSPNAKFLQHI
QSANFGPSPARRGIVSSMHNVMKDTILNFWGDSLHLPSERGYNAMQVAAALPGDXEAVKM
LAKSAKPSDINFKTSATPTPLNLACLGGDNEVWGLVGGCHGIDINQKSGSDKNTVLEY
ATSKGDSFLVQKILAHGTGVDVNCENNLCQTPLHLAVEGGGPKIVSSLLKAGAVVWRLD
DNBSVLSSAIVPGRKKGVLGIYNKLLDRGADINLDSGHNILFDQCCLGGYVNVLDK
LIQQGVFVNRMSRIRIMVYAAISENEHAIKELANAGQVNVNFWNNPSSRHSNHLIMV
AVADGNAGLLKTLVSEGGDVKSGKDGNTALNYAVSHSDKPEGNKAIKILSRNSVGT
NRDILTQKNNAGDTPHRAALKSGNTESVQNTLSAVHPRYAKSILLTARDKBYTPEHYT
VGVNMDVGRSITLESMLSKGVNHLGEIVGAQSGNPRTPHRAIKISDYRAADMIIGSL
SKTELSELSQLTDINGDTPHLGLSCQSGNVENTOPFLGGLOKRELPTLTETANKDTP
LHDAIENDDIKSAKMMIRKCNKRELAVLXCKDSFQHTVLTITADQVIANFESKDLQ
GLNGLAVXRLLKQGLKLDLYNTRMMSDDTVAHCALLSDNKYAQKILKSCNHDITVRGNS
NMQSLSECIIDDSKYKGGIYKSLPSKLYKLBARAASASYERLSSEGGDVSSTVET
NSTEVSANPEVARSSCAVSFKHEVQETGVDTGSPSDIESLERLSDTLGSNDFQRMAD
LDQEIANTVSGLPENTQVAVSQQQARSBSGQANAGVQCKENQR*

```

ORIGIN

1	atgttcagatc	caaaacaagg	tgatccagaa	caaaatcaaa	ctaaccctag	tggttgatatt
61	caggatcaaa	gtcagcaaga	tcaacaggaa	caagatcagc	agcaagggagc	agttgagtggt
121	gctgttcgga	atagtcctat	tgaagagagag	agagtagctg	ctcctgagag	tgaagattta
181	tatactgtga	ttatacctaa	gggtaaaaga	actgctgctc	caatttttga	aagaagagctc
241	cctactcctg	aaccyaaagt	agaagatgat	gaagatttac	ctcctacatt	accgcccaaga
301	acatttttcg	gagaaggata	tgatgaagtt	ggagttagta	tgctactgtg	tagtctgtgc
361	atataccaac	ctcccatagt	tcaagatagt	aactctatatt	caagtattgg	tggcgtaacc
421	caagaagcac	aatatgatgc	agcagctcgg	gctggtgggc	caagaaagtt	tttgtatggg
481	ccatatacat	tcagtaatgg	tcaggaaact	atggactttg	aatttgatac	tccttgggcca
541	gatgttaagg	atgcagtttt	aggtaataaa	gagataaaag	zagagtgggt	aactacttct
601	gggcccagta	gtgatattgc	tgataggata	gttgcttcta	aaggtgattt	gtctgaggat
661	caagtagaag	aaatccttga	tatttatatt	atgaatgaat	cagaaatcgc	tgaaggctatt
721	ctaatccat	tacatgctga	tgthgataat	aatcctgtta	aaggtgctaa	gaatgtgatg
781	acattgatgc	atctagttta	tgcatgtgat	gttgatccac	gtatagtaaa	agctthagga
841	gaggtggaaa	atgatgaagg	tgatttagga	gctaatgctt	ataatgtttt	agatagtgag
901	ggtaatcttc	ctttacatca	tgctgcaaa	aattgtacag	gggataagtt	aaagctttgt
961	atggagaaaa	caaagactga	ttttattgat	actgcgaatt	tcggagaatca	atccctttta
1021	catattatta	catagaagcc	agattgctct	gtattagata	ttgaagagtt	tacaagccgt
1081	aatttagatt	ttggacttgt	agatggagat	ggtaaaaatc	ctttacatca	tgctgttgaa
1141	catthgcac	ctgtttatct	taagggcgta	atggaccatg	taaaaaatag	tagtgaggtt
1201	caagatttag	taaatgatcc	tgattatttt	ggaaatacta	tagctcaatta	tgcagtcaag
1261	aataaaaata	ctgatttaac	attgtttcaac	atgctgaag	cttcaggagc	tgatttaaat
1321	gttaggaatg	tagttggtcg	agctcccaata	catgttgctt	cttctaattg	taaggctaat
1381	gcagtttctg	gaattgtatc	atgtggtatt	gacgttaatt	ctcaagatgt	gaatggagat
1441	acaccacttc	atattgctgt	tgaaggcggt	agtatggaga	cggattatgc	agtgcttaaat
1501	cagagaggtg	ctgatgttag	tgtccagaat	aacgatggag	ttacaactat	gcttagtgtc
1561	gctaaatatg	ggatataagg	tgtataaaaa	gctttagggt	cagctaaacc	aaatattaaa
1621	ggtgaagaca	ctgttgctaa	atcattgctg	atggaggatt	acaaagggtt	tacacccttg
1681	catttttgag	ctggtggtgg	tagcagagat	acattccgtg	tcgtaagaaa	aaattatgaa
1741	aaatgtcatg	acttagctac	tattagggca	gctttaatgc	aagatagaag	tggtagtgag
1801	cttgtaaat	taggggattt	tgaagtgaa	aatatattgg	gttcgccaaa	tgcaaaattc
1861	ttgcagcata	ttcaatcagc	aaattttggt	ttttctccag	cgcgaaggag	tatagtatcg
1921	ttcaatcaca	atgtaatgaa	agatatctta	aattttgttg	gggatttggt	acacotacca
1981	agtgagcgtg	ggtataatgc	aatgcagggt	gctgctttgt	ttggtgacaa	agaagcagtg

```


2041 aaaatgcttg ctaaaagtgc taagcnaagt gatcttaatt ttaagaette agcaactect
2101 actcogttaa atcttgcattg tottagaggt gataatgagg tagtacgtgg gttagtaggt
2161 caacatggta ttgacattaa ccaacgtatg ggaagtgata aaaaactctg attgcattat
2221 gcaatcagca aaggagatag tttctcttgg caaaagatat tagtcatac tggagttgat
2281 gctaaattgt agaataacct aggtcaaacg cctttacatt tagcagttga gggaggagat
2341 cctaagatag tatctctctt tcttaagctt ggtgcagtag ttaacgtctt ggalgataat
2401 ggtagatctg tactttcttc tgcgatatgt ccaggtagaa aagaaaaggg agtgcctggg
2461 atagttaata aattgctgga tagaggtgca gatcttaatt tagatggaga ccaaatata
2521 ctttttgatc agtgtctaa ggttgatata aataatgtat tagataagtt aatacaacaa
2581 ggggttgaaq ttaactgaaa tagtgaataa cgtccaatgg tttatgctgc aatatctggg
2641 aatgagcatg ctatcaaatc attagctaat gctggctggg atgttaattga agtctaatc
2701 aatccatcta gtaggcattc aggaatactc ttaattatgg tgcagtagc agatggtaac
2761 gcaggctctc ttaaacattc agttcttgaa ggtgctgatg ttggttaatac tggaaaagac
2821 ggttaatacag cgttacatta tgcctgttag cttcagata aagagtttgg taataaagct
2881 ataaagatat taatttcacg taatagctgt gggactaata gagatattct tactcaaaag
2941 aataacgcag gtgatacacc tttacatgaa gctcttaagt caggtaatac taattctgta
3001 cagatatact taagtgtctg acatccaaga taagcaaaag agatattaac agccagagac
3061 aaagaagggg acacacacaa gcattatact gttggagtaa ataagtgtga tgttggtaga
3121 agtattctag agtctatgct ctctaaaggt gtgaataatc ttggagagat tgttggagca
3181 caggatagta attttcgaa acctctgcac gctgctatta aaktatctga ttatcgtgct
3241 gggacatga taataggtag cttatcgaaa acagaattgt czaagttatc gcaatbaaa
3301 gatattaacg gggatacacc actacatctt tcttctcagt ctggtaatgt cgagatgaca
3361 caattcttct cttgaggttt ggataaaagt gaattaccta agacattaaa gatagcaaat
3421 aaaaatggag ataactcttt acatgatgct ataagaatg atgatattaa atctgcaaaa
3481 atgatgatta ggaattgtaa caaagaagaa cttgctaatt tattaaaatg caaagatagt
3541 ttggtaata cagtattgca tactattgct gaaccaagta ttggaatcc agaataaag
3601 aaagaccttg atggtttgat gaatttagca gtgaaaaggg taagaatca agatctgaaa
3661 gatctagtta atacgcgaaa taactctgac gctactgttg cacattgtgc tcttttatcg
3721 gatctgaaat atgctcaaaa gatactbaaa tcatgtaacc atgatacatt agtgagagga
3781 aatagtaata atcaatcttt atcagaggtg attcgtgatg atagtaataa taaaaaaggt
3841 ggaattctta gtaagtcttt attttcaaaa ttaaaagaa c ttgaggcaag agctgcacgc
3901 gctagttatg aagaattatc tagtatcagt agtggtagtg atgttctctc tgtatcaaca
3961 aatagcacag aagtaagtgc agtacctgaa gtaggcaagaa gtagtgggtg tgtgtcttcc
4021 aaacatgtgc aagaaacagg agttgacacg tctggctcct ctgatataga aagtttagag
4081 agattatctg atactagtct tgggtcaaat gatcttgatc agogaatggc agatttagat
4141 caaqaatatg caaatattgt tagtggttta ccagaagtta ccaggttagc tgtaaagtaa
4201 caacaagcag catctctctg ttcaaggtcaa gctgctgctg tgaacaaaa agagatgcag
4261 agataa

```

//

Disclaimer | Write to the Help Desk
NCBI | NLM | NIH

EXHIBIT 2



[PubMed](#)
[Nucleotide](#)
[Protein](#)
[Genome](#)
[Structure](#)
[PMC](#)
[Taxonomy](#)
[OHM](#)
[Books](#)

[My NCBI](#)
[Sign In](#)
[Register](#)

Nucleotide

[Limits](#)
[Preview/Index](#)
[History](#)
[Clipboard](#)
[Details](#)

[Display](#)
[GenBank](#)

Range: from begin to end
☐ Reverse complemented strand
Features:

☐ I: AF252298. Reports ...[gi:12658962] The record has been replaced by 37528969

Comment	Features	Sequence
---------	----------	----------

```

LOCUS       AF251298                      1173 bp    DNA                    linear   BCT-05-FEB-2001
DEFINITION  Ehrlichia canis 43 kDa surface protein gene, complete cds.
ACCESSION   AF251298
VERSION     AF251298.1 GI:12658962
KEYWORDS
SOURCE      Ehrlichia canis
ORGANISM    Ehrlichia canis
            Bacteria; Proteobacteria; Alphaproteobacteria; Rickettsiales;
            Anaplasmataceae; Ehrlichia.
REFERENCE   1 (bases 1 to 1173)
AUTHORS     McBride,J.W., Cozart,R.R., Breitachewdt,E.B. and Walker,D.H.
TITLE       Immunodiagnosis of Ehrlichia canis infection with recombinant
            proteins
JOURNAL     J. Clin. Microbiol. 39 (1), 315-322 (2001)
PUBMED      11196790
REFERENCE   2 (bases 1 to 1173)
AUTHORS     McBride,J.W. and Walker,D.H.
TITLE       Direct Submission
JOURNAL     Submitted (04-APR-2000) Pathology, University of Texas Medical
            Branch, 301 University Blvd., Galveston, TX 77555, USA
COMMENT     [WARNING] On Oct 6, 2003 this sequence was replaced by a newer
            version gi:37528969.
FEATURES             Location/Qualifiers
     source           1..1173
                     /organism="Ehrlichia canis"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:944"
     CDS              1..1173
                     /codon_start=1
                     /translation="MSPCKQGEPEONQTNPSGDIQDGSQQDQCBQQQQQGVAVGGAVGN
                     SPIERSRVAAPESEDLYTVIIFPKGRHTAAILERKSFTPEPKVEDGEDLPPTLPPRTF
                     SGEGYDDWGVSMPTVSRGIYQEPPIVCOSNLYSSIGGVQEAGYDAARACGPFRKPLYG
                     PTFPNHQEQEINDFEPTTPMPDVNRNAVLGNKKEIKEWLTTSQPVVDIADRIIVASKGNLS
                     EDQVEZILDIIPMWESIAEGISNP LHADVNNPVRGARNTLTSLVYACDVDPRI V
                     KALGEVDEDCDLGAMAYNVLESGCNLP LHHAAAGCTCDKLKLMEXTKTSTFDYAN?
                     ANQSPLHIITQSPDCSVLDIEFTSRNLDRGINVDGDKNPLHHAVERHLPPVNLKGA"
ORIGIN
1 atgtcagatc caccacagg tgcaccaga caccatcaa ctaccctag ttgtgatatt
61 caaaatcaaa atcaaacaaa tcaccacaaa caaatccagc accaaagcgc agtttgttgc

```

```

121 gctgtttgga atagtccat tgaagagag agagttagctg ctctggagag tgaagattta
181 tatactgtga ttatacctaa gggtaaaaaga actgctgctc caatttttga aagaaagtct
242 cctactcctg aacggaaagt agaatgatgat gaagattttac ctctacatt accgcaaga
301 aacttttcag gagaaggata tgatgaaggt ggagttagta tgcctactgt tagtcgtggc
361 atataccaac ctcccatagt tcaagatagt aatctatatt caagtattgg tggcctacca
421 caagaagcac aatattgatgc agcagctcgg gctggtgggc caagaaggtt ttgtatggg
481 ccatacacat tcaataatgg tcaggaaatt atggactctg aatttgatgc tcttggcca
541 gatgttagga atgcagtttt aggttaataaa gagataaaaag aaggttggtt aactacttct
601 gggccagtac gtgactttgc tgataggata gttgcttcta aaggttggtt gctcgaggat
661 caagtagaag aaatccctga tattatattt atgaatgaat cagaaatcgc tgaaggtact
721 tcaaatccat taatggctga ttttgataat aatcctgtta aaggtgctaa gaatgtgatg
781 aacttgatgc atctagtta tgcattgtgat gttgctccac gtatagtaaa agcttttaga
841 gaggtggaaa atgatgaag tgatttagga gctaatgctt aaatgtttt agatagttag
901 ggtaatcttc cttacatca tgcctcaag aattgctcag gggataagtt aagctttgt
961 atggagaaaa caaagactga ttttattgat actgcaaat ttgcaatca atcccttta
1021 catattatta cacagaagcc agattgttct gtattagata ttgaaggtt tacaagcgt
1081 aatttagatt tggacttgt agatggagat ggtaaaaatc cttacatca tgcgtctgaa
1141 cttttgcac ctgttaactt aaagggggcg taa

```

//

Disclaimer | Write to the Help Desk
NCBI | BLAST | NPI

X. RELATED PROCEEDINGS APPENDIX

NONE.